Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D

This study examines cost sharing for novel second-line diabetes treatment agents under Medicare Part D.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research